MedPath

Prevention of asprin-induced small-intestinal injury by Poraprezinc

Not Applicable
Conditions
small-intestinal injury
Registration Number
JPRN-UMIN000003687
Lead Sponsor
Department of Endoscopy, Hiroshima University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with inflammatory bowel disease 2. Patients with digestion and absorption disorder 3. Patients who is taking Poraprezinc 4. Patients who is taking other medicines for gastritis, such as Misoprostol, Rebamipide, etc. 5. Patients who is taking Penicillamine and Levothyroxine sodium 6. Patients with stenosis of gastrointestinal tract and severe adhesion 7. Pregnant and nursing women 8. Patients with severe ulcerative lesion with capsule endoscopy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Incidence of asprin-induced small-intestinal injury (redness, erosion, ulcer) 2. Evaluation of endoscopic findings with capsule endoscopy after taking Poraprezinc or not.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath